Navigation Links
Drug Device Combination Products Market is Expected to Reach USD 115.1 Billion Globally in 2019: Transparency Market Research
Date:12/24/2013

NEW YORK, December 24, 2013 /PRNewswire/ --

According to a new market report published by Transparency Market Research "Drug Device Combination Products Market (Drug Eluting Stents, Infusion Pumps, Photosensitizers, Orthopedic Combination Products, Wound Care Combination Products, Inhalers, Transdermal Patches, Intraocular Implants and Drug Eluting Beads)- Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019," the global drug device combination productsmarket was valued at USD 66.0 billion in 2012 and is expected to grow at a CAGR of 7.9% from 2013 to 2019, to reach an estimated value of USD 115.1 billion in 2019.

Browse the full report with complete TOC at http://www.transparencymarketresearch.com/drug-device-combination.html

Drug device combination products are therapeutic products that combine a drug and a medical device chemically and/or physically, to beproduced as a single product. These products can be designed for local as well as systemic drug delivery.With the advances in medical technology, medical devices have changed their definition to more complex devices which assist in improving the efficiency of drugs in therapeutic treatments. These innovations have also made it difficult for regulatory agencies to classify and provide guidelines for safety and validation of these products.Newer developments in drug device combination products have yielded several products for targeted drug delivery within the body. Clinical trials for drug device combination products are more comprehensive and expensive coupled with complications as compared to those required for individual drug and device.

Growing elderly population combined with rise in risk for cardiovascular diseases, asthma and various other chronic disorders contribute to the growth of this market particularly in emerging economies of Middle East, India and China. Moreover, technological advancessuch as biodegradable implants coupled with increase in access and recognition of these technologies in emerging market, will serve as an opportunity for investors to invest in.

The global market for drug device combination products has been studied from the perspective of current widely used various product types.The report provides a detailed analysis of drug eluting stents which are segmented into coronary stents and peripheral vascular stents while the infusion pumps include implantable infusion pumps and ambulatory infusion pumps. Inhalers include metered dose inhalers, dry powder inhalers and nebulizers. The others segment comprises intraocular implants and drug eluting beads. The market estimations for transdermal patches, orthopedic combination products such as bone graft implants and antibiotic loaded bone cements, wound care combination products and photosensitizers have also been provided in the report for the forecast period 2013-2019.

The overall market for drug device combination products is fragmented owing to number of small players involved in respective product segments. In 2012, transdermal patches accounted for the largest share by revenue at USD 25.1 billion of the total drug device combination products market. However, due to the product recalls and consequent stringent regulatory approval procedures, the overall market revenue is expected to decline during the forecast period in the U.S and Europe.The market for inhalers accounted for the second largest share at over USD 20billion in 2012. It is estimated that the global market for inhalers will grow at a CAGR of over 8% from 2013 to 2019, owing to its high incidence rates of asthmatic and chronic obstructive pulmonary disease (COPD) patients.

Geographically, North America dominatedthe global market for drug device combination products in terms of revenue generation and is expected to maintain its position throughout the forecast period. Theadoption of drug eluting stents, implants, growing elderly population and rise in incidences of hypertension and obesity in the U.S., is expected to contribute to the leadership of the North American market. Europe was the second largest regional market for drug device combination productsin 2012, owing to the increased demand for drug eluting stents and infusion pumps.

Related & Recently Published Reports by Transparency Market Research

Coal Fired Power Generation Market: http://www.transparencymarketresearch.com/coal-fired-power-generation-market.html

Amines Market: http://www.transparencymarketresearch.com/amines-market.html

Teleradiology Market: http://www.transparencymarketresearch.com/teleradiology-technology-Market.html

Orthobiologics Market: http://www.transparencymarketresearch.com/orthobiologics-market.html

The global drug device combination products market is dominated by few major players including Boston Scientific Corporation, Medtronic, Inc., Abbott Laboratories, Inc., CareFusion Corporation and Allergen, Inc.

The global drug device combination products marketis segmented as follows:

Drug Device Combination Products Market, by Product Type

  • Drug Eluting Stents
    • Coronary Stents
    • Peripheral Vascular Stents
  • Infusion Pumps
    • Implantable Infusion Pumps
    • Ambulatory Infusion Pumps
  • Photosensitizers
  • Orthopedic Combination Products
    • Bone Graft Implants
    • Antibiotic Loaded Bone Cement
  • Wound Care Combination Products
  • Inhalers
    • Metered Dose Inhalers
    • Dry Powder Inhalers
    • Nebulizers
  • Transdermal Patches
  • Others
    • Intraocular Implants
    • Drug Eluting Beads

Drug Device Combination Products, by Geography

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World (RoW)

Browse all Medical Devices Market Research Reports @ http://www.transparencymarketresearch.com/medical-devices-market-reports-6.html

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers, and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Sheela AK
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Web: http://www.transparencymarketresearch.com/
Blog: http://www.tmrblog.com/
Blog: http://www.culrav.org/pr/author/tmrrelease

 


'/>"/>
SOURCE http://www.transparencymarketresearch.com/
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Medical Device Developers - Network at BIOMEDevice Boston Next Week
2. Enox Biopharma, Inc. To Present Today At IN3 Medical Device 360 Conference In London
3. Nearly 300 Medical Device, Healthcare Professionals Attend First National Conference on Value-driven Engineering
4. Advance Recruitment Delighted With Positive Outlook for Medical Device Sales Industry
5. Endocrinology Market to 2018 - Advanced Injection Devices for Growth Hormone and Somatostatin will Improve Ease of Use for Patients
6. Angioslide Announces FDA 510(K) Clearance of PROTEUS(TM) Below The Knee Device
7. Middle East and Africa Endoscopy Devices Market Outlook to 2017 - Flexible Endoscopes, Rigid Endoscopes, Endoscopy Visualization Systems, Capsule Endoscope Systems and Others
8. Staffing and Performance Benchmarks for Quality Function Highlight New Medical Device Study
9. Coloplast Wins Patent Infringement Verdict Against Generic Medical Devices, Inc.
10. New Chronic Wound Treatment Device Receives Award from Veterans Healthcare Program
11. Study of First-in-Class WATCHMAN® Device Shows 75 Percent Reduction in Stroke Risk in Patients with Atrial Fibrillation Not Eligible for Oral Anticoagulation Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... February 10, 2016 The campaign aims ... 5 years reach the milestone of their 5 th ... ensure 2,50,532 children between the ages of 2 - 5 ... --> The campaign aims to ... reach the milestone of their 5 th birthday   ...
(Date:2/9/2016)... 9, 2016  Insulet Corporation (NASDAQ: PODD ) (Insulet ... technology with its OmniPod ® Insulin ... has been appointed to Insulet,s Board of Directors. With his ... of whom are independent. --> ... and finance experience and a deep knowledge of accounting, financial ...
(Date:2/9/2016)... QGEN ; Frankfurt Prime ... Genomics to develop and promote comprehensive solutions for ... --> QGEN ; Frankfurt Prime Standard: QIA) ... develop and promote comprehensive solutions for next-generation sequencing ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... ... It’s that time of year when most people have forgotten all about their New ... (IAAM), Hall of Fame athlete and Garrison Forest School athletic director since 2005, knows ... of her first decisions when her IAAM two-year presidency began last July was to ...
(Date:2/9/2016)... Albuquerque, NM (PRWEB) , ... February 09, 2016 , ... ... proceeds from its Heart Rate Variability scans throughout the month to the American Heart ... to spot the first signs of heart disease and Health Quest’s INSiGHT Pulse Wave ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... Snowfall4pod Digital, creators of the gContentManager & Distribution Network, today announced the ... and print-on-demand network. , AVALANCHE allows enterprise customers to license and create ...
(Date:2/9/2016)... ... February 10, 2016 , ... The Journal of Pain Research ... playing field .” , As corresponding author Dr John F. Peppin says “Terminology matters, ... diagnose our chronic pain patients. ‘Chronic cancer pain’ and ‘chronic non-cancer pain’ are ...
(Date:2/9/2016)... ... 2016 , ... METTLER TOLEDO has published a new guide ... understanding of the techniques they use so they can more easily spot potential ... and rework to create a leaner overall lab experience. , The new ...
Breaking Medicine News(10 mins):